Humacyte Inc’s filing revealed that its Chief Commercial Officer Scheessele William John acquired Company’s shares for reported $9999.0 on Apr 14 ’25. In the deal valued at $1.54 per share,6,493 shares were bought. As a result of this transaction, Scheessele William John now holds 22,018 shares worth roughly $36990.24.
Then, Sander Dale A. bought 20,000 shares, generating $30,600 in total proceeds. Upon buying the shares at $1.53, the CFO and Chief Corp. Deve. Off. now owns 40,600 shares.
Before that, Parikh Shamik J bought 7,500 shares. Humacyte Inc shares valued at $11,625 were divested by the Chief Medical Officer at a price of $1.55 per share. As a result of the transaction, Parikh Shamik J now holds 7,500 shares, worth roughly $12600.0.
H.C. Wainwright reiterated its Humacyte Inc [HUMA] rating to a Buy in a research note published on December 20, 2024; the price target was $15. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Piper Sandler also remained covering HUMA and has increased its forecast on August 14, 2023 with a “Neutral” recommendation from previously “an Underweight” rating. Cantor Fitzgerald started covering the stock on June 22, 2023. It rated HUMA as “an Overweight”.
Price Performance Review of HUMA
On Thursday, Humacyte Inc [NASDAQ:HUMA] saw its stock jump 8.39% to $1.68. Over the last five days, the stock has gained 7.01%. Humacyte Inc shares have fallen nearly -66.73% since the year began. Nevertheless, the stocks have fallen -45.10% over the past one year. While a 52-week high of $9.97 was reached on 01/02/25, a 52-week low of $1.15 was recorded on 04/08/25. SMA at 50 days reached $2.7750, while 200 days put it at $4.8874.
Levels Of Support And Resistance For HUMA Stock
The 24-hour chart illustrates a support level at 1.5867, which if violated will result in even more drops to 1.4933. On the upside, there is a resistance level at 1.7367. A further resistance level may holdings at 1.7933. The Relative Strength Index (RSI) on the 14-day chart is 38.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.1075, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 29.33%. Stochastics %K at 50.16% indicates the stock is a holding.
How much short interest is there in Humacyte Inc?
A steep rise in short interest was recorded in Humacyte Inc stocks on 2025-03-31, growing by 1.66 million shares to a total of 27.14 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 25.48 million shares. There was a rise of 6.12%, which implies that there is a positive sentiment for the stock.
